The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians
Abstract
DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the available evidence on various pharmacologic treatments to prevent fractures in men and women with low bone density or osteoporosis. METHODS: Published literature on this topic was identified by using MEDLINE (1966 to December 2006), the ACP Journal Club database, the Cochrane Central Register of Controlled Trials (no date limits), the Cochrane Database of Systematic Reviews (no date limits), Web sites of the United Kingdom National Institute of Health and Clinical Excellence (no date limits), and the United Kingdom Health Technology Assessment Program (January 1998 to December 2006). Searches were limited to English-language publications and human studies. Keywords for search included terms for osteoporosis, osteopenia, low bone density, and the drugs listed in the key questions. This guideline grades the evidence and recommendations according to the ACP's clinical practice guidelines grading system. RECOMMENDATION 1: ACP recommends that clinicians offer pharmacologic treatment to men and women who have known osteoporosis and to those who have experienced fragility fractures (Grade: strong recommendation; high-quality evidence). RECOMMENDATION 2: ACP recommends that clinicians consider pharmacologic treatment for men and women who are at risk for developing osteoporosis (Grade: weak recommendation; moderate-quality evidence). RECOMMENDATION 3: ACP recommends that clinicians choose among pharmacologic treatment options for osteoporosis in men and women on the basis of an assessment of risk and benefits in individual patients (Grade: strong recommendation; moderate-quality evidence). RECOMMENDATION 4: ACP recommends further research to evaluate treatment of osteoporosis in men and women.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [53]
In the citing paper
“Removing these affected trial reports would likely alter findings in five reviews and guidelines.51–54 56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [53]
In the citing paper
“The linked guideline from the American College of Physicians53 (114 citations, March 2018) references the same four affected trial reports as evidence for bisphosphonate use in populations at increased risk of falls.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [53]
Citations
Cites
9 retracted
Wimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedSato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1743 · Cited by 139 · cited 1×
“78]) (56), calcitonin decreased the risk for vertebral fractures (RR, 0.”
BackgroundRetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132 · cited 2×
“Fair-quality evidence shows that calcitonin reduces vertebral fractures (83, 84).”
BackgroundRetractedRisedronate therapy for prevention of hip fracture after stroke in elderly women [RETRACTED]
(2005) · Neurology · doi:10.1212/01.wnl.0000152871.65027.76 · Cited by 81
RetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69
RetractedSatō, Y., Asoh, T., Kaji, M., & Ōizumi, K. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.12.2487 · Cited by 63 · cited 1×
“67]) (59, 118, 134), whereas the pooled estimate from 2 studies showed that ibandronate had a lower risk for serious gastrointestinal adverse events (OR, 0.”
ResultRetractedSato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2006) · Movement Disorders · doi:10.1002/mds.20825 · Cited by 56
RetractedBeneficial Effect of Etidronate Therapy in Immobilized Hip Fracture Patients[Retracted]
Satō, Y., Kanoko, T., Yasuda, H., Satoh, K., & Iwamoto, J. (2004) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000122877.28631.23 · Cited by 21 · cited 1×
“67]) (59, 118, 134), whereas the pooled estimate from 2 studies showed that ibandronate had a lower risk for serious gastrointestinal adverse events (OR, 0.”
ResultRetractedSatō, Y., Honda, Y., & Iwamoto, J. (2006) · Bone · doi:10.1016/j.bone.2006.04.025 · Cited by 20
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 22
- Avenell A, 2005, Cochrane Database Syst Rev, CD000227
- Cranney A, 2000, Cochrane Database Syst Rev, CD001983
- Cranney A, 2006, Cochrane Database Syst Rev, CD003376
- Palmer S, 2005, Cochrane Database Syst Rev, CD005015
- Bone HG, 2000, J Clin Endocrinol Metab, 85, 720
- Homik J, 2000, Cochrane Database Syst Rev, CD001347
- Sato S, 2003, J Rheumatol, 30, 2673
- Reid IR, 1994, J Clin Endocrinol Metab, 79, 1595
- 10.1016/j.amjmed.2004.05.019 · DOI
- 10.1016/j.bone.2004.09.003 · DOI
- Homik JE, 1999, J Rheumatol, 26, 1148
- 10.1007/s00198-004-1713-3 · DOI · Paper page
- 10.1093/jnci/90.18.1371 · DOI · Paper page
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Blair MM, 2000, J Fam Pract, 49, 839
- 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W · doi:10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co;2-w
- Cortet B, 1999, Rev Rhum Engl Ed, 66, 214
- Geusens P, 1997, Bone, 20, 9S
- Meunier PJ, 1997, J Clin Endocrinol Metab, 82, 2784
- Silberstein EB, 1992, J Nucl Med, 33, 1
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
Cited by
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
“Osteopor osis therapies, including alendronate, risedronate and teriparatide, reduce the risk of vertebral fractures and maintain bone mineral density in those taking glucocorticoids.(13,52,53)”
BackgroundQaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Self-citationThe Advisory Board of the National Osteoporosis Guideline Group, Kanis, J. A., Harvey, N. C., Cooper, C., Johansson, H., Odén, A., & McCloskey, E. V. (2016) · Archives of Osteoporosis · doi:10.1007/s11657-016-0278-z · Cited by 421
Evaluation and Management of Vertebral Compression Fractures
Alexandru, D., & So, W. (2012) · The Permanente Journal · doi:10.7812/tpp/12-037 · Cited by 309
“It is estimated that approximately 44 million Americans have osteoporosis and that an additional 34 million Americans have low bone mass.(17) Studies have suggested that having 1 VCF increases the risk of future VCFs.”
BackgroundGreen, J., Czanner, G., Reeves, G., Watson, J., Wise, L., & Beral, V. (2010) · BMJ · doi:10.1136/bmj.c4444 · Cited by 275
“Oral bisphosphonates are the recommended first line treatment for primary and secondary prevention of osteoporotic fracture in both men and women in Europe and in North America.”
Background
Metadata
- Authors
- Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians
- Affiliations
- University of Arkansas at Little Rock (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2008-09-16
- Volume
- 149
- Issue
- 6
- Pages
- 404-415
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2128498016
- Cited by
- 180
- References
- 151
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 3 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 9 · 2013: 17 · 2012: 14
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, fragility fractures, pharmacotherapy, bisphosphonates, men, women, risk-benefit assessment
- MeSH terms
- Bone Diseases, Metabolic, Female, Humans, Male, Osteoporosis, Risk Factors, United States, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. https://app.cochat.ai/papers/10.7326/0003-4819-149-6-200809160-00007
- The paper
- Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians. (2008). Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-149-6-200809160-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.